pfizer settl humira patent reduc
likelihood at-risk launch
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
hold strong portfolio market pipelin
drug increas competit compani key drug humira
slow growth compani total sale
higher portion earn due higher margin revenu
humira key determin perform next
approv rheumatoid arthriti psoriasi crohn
diseas humira continu grow market
penetr rate averag long-term
challeng emerg despit favor near-term outlook
humira uncertainti around encroach competit
like weigh investor sentiment toward compani
particular new jak inhibitor antibodi repres
major drug advanc rheumatoid arthriti psoriasi
like lead market share loss humira also
humira biolog composit longer-last patent
may deter gener complet follow key patent
loss patent loss europ model close
annual revenu declin humira
well-posit next gener immunolog drug
particular pipelin drug shown improv efficaci safeti
humira current lead treatment option
beyond immunolog cancer drug imbruvica next-biggest
sale contributor imbruvica strong clinic data sever form
blood cancer lead peak sale billion
remain drug larg matur patent expir long
past manufactur specif dose complex
look forward pipelin weight heavili toward new
cancer drug particular pipelin lead
increasingli strong posit blood cancer compani
abl leverag solid entrench imbruvica launch
new drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
drug compani strong exposur immunolog
oncolog compani top drug humira repres half
compani current profit compani spun abbott earli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pfizer settl humira patent reduc
likelihood at-risk launch
increas fair valu estim
follow humira licens agreement
allow access market
biosimilar version humira novemb
announc expect launch
biosimilar humira at-risk time close
howev follow announc at-risk launch
look unlik strong patent protect
develop around humira proven
difficult penetr initi expect
typic noncomposition-of-matt patent hold
gener competit howev case complex
humira biolog structur larg amount
addit noncomposition-of-matt patent make
case at-risk launch stronger addit year
exclus drive fair valu estim
provid year strong cash flow
expect use help fund research
develop next-gener drug support firm
narrow moat howev expect signific declin
humira sale follow build-up biosimilar
competit start declin
project follow declin sever
biosimilar version humira like drive price
drug
increas fair valu estim
follow humira licens agreement
allow access
 market biosimilar version humira nov
announc expect launch
biosimilar humira at-risk sometim close
howev follow announc at-risk launch
look unlik strong patent protect
develop around humira proven
difficult penetr initi expect
look remain compani key valuat driver
off-set eventu like humira sale declin
compani next-gener immunolog drug target
jak pathway new pathway seem
offer better efficaci improv side effect profil
potenti leukemia also compani sever
late-stag cancer drug help mitig
eventu humira sale declin billion
total sale project slightli manag
guidanc billion bottom line
next three year expect improv margin larg
driven higher contribut total sale specialti
drug carri high margin also
partnership royalti humira began expir
help improv gross margin weight averag
cost capit use cost equiti market
rate cost debt
larg base low volatil cash flow
divers inelast product portfolio rate
uncertainti medium slightli higher
pharma peer group partli due high product
concentr risk surround humira half total
estim bull case probabl
bear case probabl project fair
valu estim rel base case scenario
analysi show moder varianc henc medium
uncertainti rate import driver valuat
far humira unknown pressur biosimilar
competit humira weigh certainti bull
case assum annual declin humira post
patent loss longer exclus period bear
case assum much rapid declin start
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
develop next gener drug larg cash
flow creat economi scale enabl
fund averag million requir new drug
strong pharma firm
creat databas intellectu insight help
increas odd success drug develop final
entrench salesforc one
sought-aft therapeut area immunolog help
firm launch next gener drug make
compani lead candid smaller drug firm need
help develop commerci innov new drug
moat trend neg sever competit
threat target humira new brand drug
launch humira key therapeut area includ
ra psoriasi crohn diseas howev
expect humira lose high degre market share
new drug slow market eros longer term
like addit humira patent
loss like bring new competit threat gener
manufactur damag partli mitig given
biolog complex manufactur market
gener version drug also less power patent
like delay competit case
agre launch
less-pow patent keep
firm bay
addit major industri headwind creat
roadblock path creat next gener
drug particular fda grown increasingli
risk-sensit approv safe drug drug
highli need area like cancer insur compani
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern around world
evalu compar effect program
aggress price negoti increas bar
believ support narrow moat base
patent-protect drug intellectu intang
power salesforc case drug firm
core moat lie portfolio patent-protect
drug howev unlik pharma peer
tend carri wide moat one drug humira repres
major sale profit
greater result emerg brand
competit humira immedi term potenti
gener biosimilar threat time frame
believ excess return like persist year
certain outlook
would need wide-moat rate model
humira sale declin begin rate
declin like gradual typic small
molecule-brand drug face gener competit
complex develop market biosimilar
nevertheless deriv enorm cash flow
current product portfolio fund on-going discoveri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
need futur innov
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
support strong dividend yield
act valuat support cash flow support
dividend look secur next year
increas entrench blood cancer
bode well growth price power remain
solid therapeut area pharmaceut
osever pipelin drug immunolog
mechan action similar drug alreadi
approv take away first mover advantag
oth high profit margin humira like caus
amplifi impact earn sale lost
jak pathway help mitig
oth price power hepat drug erod
significantli past year may put
pressur next gener hepat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
despit high depend one key drug hold
strong balanc produc robust cash flow
next sever year recent acquisit
increas debt ebitda ratio time
expect strong cash flow reduc acquisit
activ bring metric time
nevertheless increas pressur humira
competit brand biosimilar like put
financi pressur compani expect pipelin
asset help mitig headwind
similar drug firm face risk new
drug failur reimburs challeng new drug
drug price cut larg payer group grow
concentr humira sale make compani
significantli expos new competit threat
humira biosimilar new brand drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ manag team demonstr
standard stewardship fail acquisit attempt
shire concern believ new abrupt
treasuri law larg caus acquisit collaps
somewhat give manag pass nevertheless
billion break-up fee relat fail shire deal
show manag gaug polit landscap
correctli billion pharmacycl acquisit
appear fair use capit imbruvica reach
turn manag specif led
gonzalez join abbott held mani
manageri post throughout career firm
howev recent led drug group start juli
brief retir rel short tenur
key field drug commerci develop
concern execut go well
leadership back gonzalez cfo
abbott year background
licens acquisit help
need redeploy strong cash flow humira
acquisit partner augment compani
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
capit research manag compani
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pfizer settl humira patent reduc
likelihood at-risk launch
increas fair valu estim
follow humira licens agreement
allow access market
biosimilar version humira novemb
announc expect launch
biosimilar humira at-risk time close
howev follow announc at-risk launch
look unlik strong patent protect
develop around humira proven
difficult penetr initi expect
typic noncomposition-of-matt patent hold
gener competit howev case complex
humira biolog structur larg amount
addit noncomposition-of-matt patent make
case at-risk launch stronger addit year
exclus drive fair valu estim
provid year strong cash flow
expect use help fund research
develop next-gener drug support firm
narrow moat howev expect signific declin
humira sale follow build-up biosimilar
competit start declin
project follow declin sever
biosimilar version humira like drive price
drug
abbvi post solid european humira biosimilar
price discount weigh growth outlook
report solid third-quart result lower
expens lead better-than-expect bottom-lin
growth expect major chang fair
valu estim base minor out-performance
view stock under-valued market like overli
concern humira biosimilar competit
appreci pipelin even though immunolog drug
humira total sale continu post steadi gain
expect biosimilar pressur begin caus
key pillar declin high concentr
profit humira like futur declin lead us
view compani moat narrow even though firm
strong develop pipelin steadi portfolio
beyond humira gain hepat drug mavyret
hematolog drug key growth driver led total
growth expect total growth rate slow
significantli european biosimilar pressur
humira start octob manag expect
intern discount includ countri without
biosimilar higher expect like
due high number simultan biosimilar launch
also expect biosimilar pressur late
ahead time frame announc settlement
biosimilar view at-risk launch
like addit pressur humira
expect bolu demand mavyret level
result minor growth drug next year
offset expect slow growth humira
mavyret believ hematolog drug
imbruvica venclexta continu post strong gain
new pipelin launch help stabil
busi expect recent launch endometriosi
drug orilissa like launch immunolog
drug risankizumab upadacitinib add three new major
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
buoy hepat drug gain post strong
report second-quart result slightli ahead
consensu expect expect
chang fair valu estim base result
view stock price pullback follow
earn releas overdon consid stock slightli
under-valued continu expect much faster
declin
immunolog drug humira versu
consensu manag guidanc due biosimilar
pressur stock appear impli even
sharper declin rel expect concern
humira outlook along drug repres
total sale lead us stay narrow moat rate
despit improv pipelin grow contribut
recent launch drug
quarter strong growth humira cancer drug
imbruvica hepat drug mavyret help propel total
sale growth expect strong growth rate
slow due humira biosimilar launch europ
mid-octob expect european biosimilar erod
humira sale annual rate close
rate seen remicad face biosimilar
competit europ addit continu model
at-risk launch humira biosimilar late
like shown willing launch at-
risk past remicad biosimilar inflectra launch
despit challeng ahead humira make
steadi progress recent launch drug hold
late-stag pipelin sever new blockbust even
imbruvica recent setback diffus larg b-cell
lymphoma studi still project drug hit peak
annual sale billion led support blood
cancer also expect hepat platform
support billion annual sever year base
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expect report imbruvica sale
billion billion due trial setback
neg studi also hurt johnson johnson
partner commerci drug impact
firm valuat dilut due johnson
johnson diversifi oper structur
complet overview blood cancer market pleas
see healthcar observ steadi blood cancer
pipelin creat opportun build exist moat
within report highlight competit posit
imbruvica multipl myeloma cll lymphoma
reach patient despit cur impact
pipelin expect recent approv endometriosi
second-lin set chronic
approv expect immunolog drug
risankizumab approv expect becom
blockbust base excel clinic data next-
gener drug help mitig upcom
new
indic lead slight fve reduct jul
report poor top-lin data imbruvica first-lin
diffus larg b-cell lymphoma dlbcl lead fair
valu estim reduct neg news put
increas pressur remain pipelin off-set
upcom biosimilar pressur key drug humira
howev believ firm solid late-stag pipelin
like slower sale eros humira due biolog
structur support narrow moat firm
neg top-lin data studi
surpris given strong data small phase
studi dlbcl despit strong data regimen
non-gcb subgroup early-stag studi low number
patient may factor skew earli
data posit made replic result larger
studi difficult addit studi
imbruvica on-going form lymphoma
skeptic drug work well follicular set
base poor earli stage data expect major
imbruvica sale focu chronic lymphocyt
leukemia cll market howev drug hold
potenti expand multipl myeloma market
data expect immpact studi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
